Safety monitoring for GLP-1 therapy itself includes: Assessment for gastrointestinal adverse effects, which are common but usually transient Monitoring for signs of pancreatitis (severe, persistent abdominal pain) Vigilance for symptoms suggesting thyroid masses (neck lump, difficulty swallowing, persistent hoarseness) Regular review of glycaemic control in diabetic patients Blood pressure and cardiovascular risk factor assessment Monitoring for gallbladder disease (right upper abdominal pain, fever, jaundice) Eye examinations for people with diabetes, particularly those with pre-existing diabetic retinopathy Renal function checks, especially if experiencing severe gastrointestinal symptoms that could lead to dehydration If you have diabetes and take insulin or sulfonylureas, your doctor may reduce these doses when starting GLP-1 therapy to prevent hypoglycaemia
The most common side effects reported with 3mg liraglutide are nausea, diarrhea, constipation, vomiting, headache, and increased mean resting heart rate
The company operates in over 20 Latin American countries and in the United States and maintains in-house R&D capabilities alongside an established regional sales and distribution network
However, we want to reiterate that the goal of this methodology update is to emphasize patient safety across all hospitals, not just consistently low performers in the Safety of Care measure group
